Janssen files EGFR-targeting antibody amivantamab with EMA
Submission based on results from phase I CHRYSALIS study
Read More
Tag: amivantamab
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
